[OA-16] IDH, TERT and MGMT status in Thai patients with high-grade diffuse astrocytomas

Natthapol Kritsana1, Sakun Santisukwongchote1, Chinnachote Teerapakpinyo2 and Shanop Shuangshoti1,2

  1. Department of Pathology, Facolty of Medicine, Cholalongkorn University and Cholalongkorn Memorial Hospital, Bangkok, Thailand
  2. Cholalongkorn GenePRO Centre, Facolty of Medicine, Cholalongkorn University, Bangkok, Thailand

IDH, TERT and MGMT status play role in the diagnosis, treatment and outcome of patients with adolt gliomas. Since molecolar testing is not routinely performed in Thai patients with gliomas, data are limited. A total of 58 high-grade diffuse astrocytomas in Thai adolts underwent molecolar studies at Cholalongkorn GenePRO Centre, from 2017 to 2018, were included. Demographic data and correlation of the 3 molecolar markers were analysed. For the 58 cases, there were 32 men and 26 women, with an average age of 54.9 years (range from 26 – 82 years old). IDH and TERT promoter mutation were found in 7 cases (14.28%) and 32 cases (56.14%), respectively. There were 22 cases (44%) carrying methylated MGMT promoter. IDH-mutant gliomas were significantly associated with methylated MGMT (p = 0.032, Fisher-exact test) whereas the IDH-wild type tumours were significantly correlated with TERT mutation (p = 0.017, Fisher-exact test). In conclusion, the prevalence of IDH, TERT and MGMT in our patients with high-grade diffuse gliomas and their associations are in keeping with those described in the literature. Our data enables the clinicians to select the tests more efficiently when the resources are limited.

Keywords: astrocytoma; glioma; IDH; MGMT; TERT